Ziccum AB (publ) (ZICC.ST)
SEK 0.35
(-9.07%)
SEK 0.35
(-9.07%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.74 Million SEK | 21941.18% |
| 2022 | 17 Thousand SEK | 240.0% |
| 2021 | 5000.00 SEK | 0.0% |
| 2020 | 5000.00 SEK | -99.24% |
| 2019 | 654 Thousand SEK | 188.11% |
| 2018 | 227 Thousand SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 280 Thousand SEK | 374.58% |
| 2024 Q1 | 2.88 Million SEK | 214.25% |
| 2024 Q2 | 59 Thousand SEK | -97.96% |
| 2023 FY | 3.74 Million SEK | 21941.18% |
| 2023 Q3 | 1.69 Million SEK | 48.51% |
| 2023 Q2 | 1.13 Million SEK | 78.37% |
| 2023 Q1 | 638 Thousand SEK | 15850.0% |
| 2023 Q4 | 919 Thousand SEK | -45.62% |
| 2022 Q1 | 9000.00 SEK | 0.0% |
| 2022 FY | 17 Thousand SEK | 240.0% |
| 2022 Q4 | 4000.00 SEK | 300.0% |
| 2022 Q3 | 1000.00 SEK | -66.67% |
| 2022 Q2 | 3000.00 SEK | -66.67% |
| 2021 Q4 | - SEK | 0.0% |
| 2021 Q3 | - SEK | -100.0% |
| 2021 Q2 | 4000.00 SEK | 0.0% |
| 2021 Q1 | - SEK | -100.0% |
| 2021 FY | 5000.00 SEK | 0.0% |
| 2020 FY | 5000.00 SEK | -99.24% |
| 2020 Q3 | 2000.00 SEK | 0.0% |
| 2020 Q4 | 3000.00 SEK | 50.0% |
| 2020 Q2 | 2000.00 SEK | 0.0% |
| 2020 Q1 | - SEK | 100.0% |
| 2019 Q4 | -1000.00 SEK | -100.4% |
| 2019 Q3 | 251 Thousand SEK | -37.72% |
| 2019 Q2 | 403 Thousand SEK | 0.0% |
| 2019 Q1 | - SEK | -100.0% |
| 2019 FY | 654 Thousand SEK | 188.11% |
| 2018 Q1 | 190 Thousand SEK | 0.0% |
| 2018 Q2 | 2000.00 SEK | -98.95% |
| 2018 FY | 227 Thousand SEK | 0.0% |
| 2018 Q4 | 35 Thousand SEK | -80.45% |
| 2018 Q3 | 179 Thousand SEK | 8850.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 93.552% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 99.392% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 92.578% |
| Mendus AB (publ) | 28.48 Million SEK | 86.847% |
| Genovis AB (publ.) | 158.23 Million SEK | 97.632% |
| Intervacc AB (publ) | 8.01 Million SEK | 53.25% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | 14.335% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 97.802% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 91.464% |
| Aptahem AB (publ) | 2.63 Million SEK | -42.436% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -262.029% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -4766.234% |
| Fluicell AB (publ) | 3.33 Million SEK | -12.253% |
| Saniona AB (publ) | 16.84 Million SEK | 77.749% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 77.162% |
| Biovica International AB (publ) | 7.29 Million SEK | 48.601% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -211.471% |
| AcouSort AB (publ) | 10.55 Million SEK | 64.487% |
| Xintela AB (publ) | 78 Thousand SEK | -4703.846% |
| Abliva AB (publ) | 137 Thousand SEK | -2635.036% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 93.495% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -86.048% |
| OncoZenge AB (publ) | 3000.00 SEK | -124800.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -2317.419% |
| CombiGene AB (publ) | 5.54 Million SEK | 32.415% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.69% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.782% |
| Corline Biomedical AB | 25.03 Million SEK | 85.03% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | 34.008% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -419.695% |
| I-Tech AB | 120.86 Million SEK | 96.9% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 97.206% |
| Cyxone AB (publ) | 5.14 Million SEK | 27.214% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | 46.851% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 64.865% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 66.634% |
| Nanologica AB (publ) | 1.44 Million SEK | -159.667% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -6969.811% |
| BioInvent International AB (publ) | 71.46 Million SEK | 94.757% |
| Alzinova AB (publ) | 270 Thousand SEK | -1287.778% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 89.361% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -156.114% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -32.778% |
| Simris Alg AB (publ) | 4.35 Million SEK | 13.941% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -2782.308% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 98.43% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -16191.304% |